Elranatamab for Multiple Myeloma
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests elranatamab, a new treatment for multiple myeloma, a type of blood cancer that has returned or hasn't responded to previous treatments. The goal is to evaluate elranatamab's effectiveness on its own for individuals who have tried 1 to 3 other treatment combinations. It suits those whose multiple myeloma has returned after treatment and who show measurable signs of the disease, such as specific protein levels in blood or urine tests. As a Phase 2 trial, the research focuses on assessing the treatment's effectiveness in an initial, smaller group of participants.
Do I need to stop my current medications to join the trial?
The trial protocol does not specify if you need to stop taking your current medications. However, it mentions that your last systemic treatment should be at least 2 weeks or 5 half-lives before starting the trial, and you can take a maximum of 160mg of dexamethasone during screening, but at least 7 days before starting therapy.
Is there any evidence suggesting that elranatamab is likely to be safe for humans?
Research has shown that elranatamab is generally well-tolerated by patients with relapsed or refractory multiple myeloma. Studies have found it to be effective and safe, with no new safety issues compared to other similar treatments. In one study, administering the treatment every two weeks reduced serious side effects from 58.6% to 46.6%, indicating its manageability. Another study confirmed that elranatamab was well-tolerated even in patients who had previous treatments targeting BCMA, a protein linked to multiple myeloma. Overall, the safety of elranatamab appears promising, with manageable side effects.12345
Why do researchers think this study treatment might be promising?
Elranatamab is unique because it targets multiple myeloma cells differently than traditional treatments like proteasome inhibitors, immunomodulatory drugs, or monoclonal antibodies. It is a bispecific antibody, meaning it can simultaneously bind to two different antigens: one on the cancer cell and another on immune cells, specifically T-cells. This dual binding action helps direct the body's immune system to attack and destroy the cancer cells more effectively. Researchers are excited about elranatamab because it offers a novel approach that could lead to more effective treatments with potentially fewer side effects, providing new hope for patients with multiple myeloma.
What evidence suggests that elranatamab might be an effective treatment for multiple myeloma?
Research has shown that elranatamab, the treatment under study in this trial, may effectively treat relapsed or refractory multiple myeloma, a type of blood cancer. One study reported that patients taking elranatamab had a median progression-free survival (PFS) of 17.2 months, meaning the disease did not worsen during and after treatment for this period. Another study found a median PFS of 27.3 months, suggesting the treatment might control the disease for over two years in some cases. Additionally, patients had a median overall survival (OS) of 24.6 months, which is the time from the start of treatment until death from any cause. These results suggest that elranatamab may significantly extend life and delay disease progression for patients with this challenging condition.46789
Who Is on the Research Team?
Ah-Reum Jeong
Principal Investigator
University of California, San Diego
Are You a Good Fit for This Trial?
This trial is for adults over 18 with relapsed/refractory Multiple Myeloma who've had 1-3 prior treatments but haven't received BCMA-directed CAR T-cell therapy. They must have measurable levels of myeloma proteins in their blood or urine and be able to perform daily activities (ECOG status 0, 1, or 2).Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive elranatamab for relapsed/refractory multiple myeloma
Observation
Treatment-free observation period for patients with sustained MRD negative response for greater than 12 months
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Elranatamab
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of California, San Diego
Lead Sponsor